Court Square to buy Center for Vein Restoration from Cortec, Massachusetts filing shows
Court Square Capital Partners has agreed to buy Center for Vein Restoration from Cortec Group, which has owned the vein care platform since 2016, according to a Massachusetts Health Policy Commission filing. No price was disclosed.
Court Square Capital Partners has agreed to acquire Center for Vein Restoration, the Greenbelt, Maryland-based vein care platform that Cortec Group has owned since 2016, according to a material change notice filed with the Massachusetts Health Policy Commission. The filing, received by the HPC on October 19, 2026 and posted to the commission's transaction list on October 23, has not been accompanied by any announcement from either firm.
What the filing says
The notice was submitted by CVR Management, LLC, the management services organization that provides non-clinical administrative support to the physician-owned practices operating under the Center for Vein Restoration name. The clinical practices themselves, including Center for Vein Restoration (MA), LLC, are not parties to the sale.
The transaction is structured as an indirect equity purchase of CVR Management. The buyer is CVR Acquisition, LLC, which the notice describes as indirectly controlled by funds affiliated with Court Square Capital Partners. The seller is CVR Acquisition Parent, LLC; CVR Management is currently owned by an affiliated fund of Cortec Group together with other investors. The percentage interest changing hands is not stated, and no purchase price appears in the filing.
The parties made their Hart-Scott-Rodino filing with the Federal Trade Commission on October 16, 2026 and sent notices to the attorneys general of Washington and Illinois the same day. A notice to the Oregon Health Authority, which reviewed CVR's purchase of Inovia Vein Specialty Centers earlier this year under the state's Health Care Market Oversight program, was due by October 23. Closing is expected on December 31, 2026.
CVR says all of its Massachusetts locations will remain open and that it plans no changes to reimbursement, referral patterns, access, quality, payer mix, service lines or service areas as a result of the sale. The filing was signed by chief financial officer Kenneth Abod on October 26.
A decade under Cortec
Cortec Group Fund VI bought CVR on January 4, 2016 as that fund's first platform investment. At the time the company operated 43 clinics in Maryland, Virginia, New Jersey, New York, Washington DC, Michigan and Pennsylvania, with founder Dr. Sanjiv Lakhanpal as president and chief executive. CVR today describes itself as having more than 130 vein center locations in more than 20 states.
Scope Research tracks 16 add-on acquisitions by CVR under Cortec's ownership, beginning with a series of single-physician practice purchases in 2019 and 2020 and moving to multi-site regional groups: Vein Center of New Mexico and VEINatlanta in 2021, Virginia Vein Care, Carolina Vein Specialists and Advanced Vein Care Center in 2022, Carolina Vein Center in 2023, Vein Specialists of the Carolinas in 2024, Coastal Georgia Vein Center and Fort Worth Vein Center in 2025, and Inovia Vein Specialty Centers in Oregon in May 2026. A sale after ten years would be a long hold by Cortec's standards and one of the larger physician-practice exits of the year.
Court Square's healthcare book
New York-based Court Square has been an active buyer of provider services platforms. Its current healthcare holdings tracked by Scope include Team Select Home Care, acquired in 2023 and since expanded through Together Homecare, Lincoln Healthcare, Pediatric Home Healthcare, Marathon Nursing and 1st Choice Pediatric Home Care; Suncrest Hospice, which it agreed to buy in April 2026 after Suncrest had absorbed Brighton Hospice; West Coast Dental; Health Union; and Soleo Health, the specialty pharmacy and infusion provider it acquired alongside WindRose Health Investors in January 2025. Vein care would be a new specialty for the firm.
Vein care has drawn steady sponsor interest because the procedures are office-based, largely elective within a covered benefit and performed in high volume, which suits the MSO model. The absence of a disclosed price in the Massachusetts notice is typical; the commission's form asks for the structure and the parties, not the consideration.
What to watch
The HPC has 30 days from a complete notice to decide whether to open a cost and market impact review, so a determination would be due in the second half of November. The Oregon HCMO docket will show whether the authority treats the change of control as a notice-only transaction or opens a preliminary review, as it did for Inovia. Neither Court Square nor Cortec had issued a release as of this writing.
Source: Notice of Material Change, CVR Management, LLC and Court Square Capital Partners, Massachusetts Health Policy Commission, received October 19, 2026 (https://masshpc.gov/sites/default/files/2026-10/20261019_CVR-Court%20Square_MCN.pdf). Background on the 2016 acquisition from Cortec Group's announcement (https://cortecgroup.com/cortec-group-announces-acquisition-of-center-for-vein-restoration/). Add-on history from the Scope Research healthcare M&A database.